CWA Asset Management Group LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 4.3% during the 4th quarter, Holdings Channel.com reports. The fund owned 341,153 shares of the biopharmaceutical company’s stock after purchasing an additional 14,105 shares during the quarter. Pfizer accounts for approximately 1.4% of CWA Asset Management Group LLC’s portfolio, making the stock its 13th largest position. CWA Asset Management Group LLC’s holdings in Pfizer were worth $17,481,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also bought and sold shares of PFE. Worth Asset Management LLC purchased a new position in Pfizer during the 1st quarter valued at $29,000. Karp Capital Management Corp bought a new stake in shares of Pfizer during the 3rd quarter valued at $27,000. Delos Wealth Advisors LLC boosted its stake in Pfizer by 100.0% in the 3rd quarter. Delos Wealth Advisors LLC now owns 800 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 400 shares in the last quarter. Legend Financial Advisors Inc. bought a new position in Pfizer in the 3rd quarter worth about $42,000. Finally, New Millennium Group LLC bought a new position in Pfizer in the 2nd quarter worth about $53,000. 67.62% of the stock is currently owned by institutional investors.
Pfizer Stock Down 0.7 %
Shares of PFE opened at $40.10 on Friday. The company has a market cap of $225.33 billion, a PE ratio of 7.32, a P/E/G ratio of 1.33 and a beta of 0.64. The business has a fifty day moving average of $43.26 and a 200 day moving average of $46.03. Pfizer Inc. has a 52-week low of $39.23 and a 52-week high of $56.32. The company has a quick ratio of 1.00, a current ratio of 1.22 and a debt-to-equity ratio of 0.34.
Wall Street Analysts Forecast Growth
A number of equities analysts have weighed in on PFE shares. Bank of America lowered Pfizer from a “buy” rating to a “neutral” rating and set a $60.00 target price for the company. in a research report on Wednesday, January 4th. Cantor Fitzgerald reissued an “overweight” rating and issued a $75.00 target price on shares of Pfizer in a report on Wednesday, February 1st. Morgan Stanley reduced their target price on shares of Pfizer from $53.00 to $45.00 and set an “equal weight” rating for the company in a report on Wednesday, February 1st. BMO Capital Markets reduced their target price on shares of Pfizer from $55.00 to $53.00 and set an “outperform” rating for the company in a report on Wednesday, February 1st. Finally, UBS Group set a $45.00 price target on Pfizer in a research note on Tuesday. Nine analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $50.38.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Get Rating).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.